to young people who do not haveu severe outcomes. no healthy young child hastc did . number two, we have effective early treatments. number three, these vaccines wane and efficacy within monthsf and we know that you cannot keep vaccinating a young person throughout their life every six months. even the article itself had three shots. i don t knowat what parent would put their child into an experimental gene therapy and offer them three shots of this vaccine for disease that s not deadly and that s we ve learned that that s not even mentioning the unprecedented adverse events and toxicities of these vaccines. so the idea that that s actually credibly being entertained that we would actually have a fine one to a four year old now ta arofr- unbelievableol. dr. corey, we appreciate your courage in speaking out on allou the issues and we ll check back with you soon. thanks so much. final thoughts when we return in the middle ages,
Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab with no Dose-Limiting Toxicities in BALLI-01. | December 11, 2021
these patients a couple weeks ago. they were in the hospital. and as a result, our department of health put out a requirement for all facilities to report any kind of ivermectin-related events. we also partnered with our poison control center in new mexico here at the university of new mexico to track these. and so, the two deaths were one was in a 38-year-old woman. another, in a 79-year-old man. they weren t they were they were both cases where the patients were not seeking appropriate-medical care for active covid infections because they were taking ivermectin instead. and so, the while people had toxicities from the ivermectin itself and we have had, actually, 15 patients just in the past two months here in new mexico call the poison control center with symptoms. these two deaths were related to delayed care from relying on an unproven treatment, rather than
it allows us to look at important policy issues in a deeper more extended format. it s called toxic beauty which explores the underregulated market for beauty and personal care products. it s an issue with serious health implications and one that has received bipartisan attention here in washington. it s hard to imagine that there are rules that limit what chemicals we can spray on food or on crops but not the chemicals we spray on ourselves every day. so a large part of my job as a formulator was to constantly do reformulations once a certain dye was thought to be even potentially have toxicities, it wouldn t wait for it to become a regulatory matter. they would be proactive in reformulation. they see vast products in
it impacts behavior. we have learned so much about lead in the last few decades, and we now know there is no safe level of lead. we also know that lead is a form of environmental racism. our kids in flint already had hi higher lead levels like kits in detroit, chicago, baltimore, philadelphia, kids already suffer from so many toxicities, lead and poverty and all of the other issues, are already burdened with higher rates of lead exposure. you didn t have to do what you did, in fact what you did you re not supposed to do. you re supposed to go through a long process to make sure your claims were vetted by 1200 other people, it is supposed to take five or ten years. you rushed out and held a press conference. why would you take that kind of risk with your own profession and break those rules in this situation? yeah, and that s the story i wanted to share with this book, the story of resistance and disobedience. i could have minded my own business, done my work as a pediatrician, seen